Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD44 in cancer.

David Naor1, Shlomo Nedvetzki, Itshak Golan

  • 1The Lautenberg Center for General and Tumor Immunology, The Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel. naord@md2.huji.ac.il

Critical Reviews in Clinical Laboratory Sciences
|December 18, 2002
PubMed
Summary

Targeting CD44, a cell surface molecule, shows therapeutic potential in animal cancer models. However, inconsistent CD44 expression and prognosis correlations require further research before human application.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Postnatal antibiotic exposure due to maternal group B streptococcus is associated with childhood asthma.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology·2025
Same author

Systemic reactions to subcutaneous immunotherapy in children and adolescents.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology·2025
Same author

Long-term outcomes of baked milk and baked egg consumption after a successful oral food challenge.

The journal of allergy and clinical immunology. In practice·2024
Same author

A short peptide protects from age-onset proteotoxicity.

Aging cell·2023
Same author

Severity and presentation of allergic reactions during baked milk oral food challenges.

The journal of allergy and clinical immunology. In practice·2023
Same author

Preclinical In-Vivo Safety and Toxicokinetics of D-PLEX100 in an Abdominal Surgery Incision Model in Juvenile Miniature Swine.

International journal of toxicology·2023

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Cancer Research

Background:

  • CD44 is a versatile cell surface molecule crucial for normal cell functions.
  • Its roles in proliferation, migration, and survival are also implicated in cancer progression.
  • CD44's involvement in cancer pathogenesis presents a therapeutic target.

Purpose of the Study:

  • To evaluate the therapeutic potential of targeting CD44 in various neoplasms.
  • To explore the possibility of developing tumor-specific anti-CD44 agents.
  • To address the conflicting data regarding CD44 expression and cancer prognosis.

Main Methods:

  • Review of animal experiments targeting CD44 using antibodies, antisense, and soluble proteins.
  • Analysis of CD44 alternative splicing and posttranslational modifications.

Related Experiment Videos

  • Examination of existing literature on CD44 expression and its correlation with prognosis in different cancers.

    • Main Results:

    • Animal studies demonstrate that targeting CD44 significantly reduces malignant activities.
    • Alternative splicing may generate tumor-specific CD44 variants, suggesting targeted therapy potential.
    • CD44 expression levels do not consistently correlate with prognosis across all cancers; some show favorable outcomes with high expression.

    Conclusions:

    • Anti-CD44 agents show promise in preclinical cancer models.
    • Development of tumor-specific anti-CD44 therapies is a potential strategy.
    • Methodological inconsistencies in research hinder definitive conclusions on CD44's prognostic value and limit clinical anti-CD44 therapy application.